KDR and pancreatic neuroendocrine tumor: It shows higher expression in patients with progressive GEP-NETs [91], and the dual angiopoietin-2/VEGFR2 blockade inhibits revascularization and tumor progression in VEGFR2-resistant pancreatic NET mice models [92].